(-)-Physostigmine salicylate
Specifications
57-64-7CAS Number
200-343-8EC Number
[(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate;2-hydroxybenzoic acidIUPAC Name
C22H27N3O5Chemical Formula
413.5 g/molMolecular Weight
Physostigmine salicylate; 57-64-7; Isopto Eserine; Physostigmine monosalicylate; NSC-757275; 2046ZRO9VU; Physostigmini salicylas; (-)-Physostigmine salicylate; CHEBI:48883; DTXSID80883232; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, mono(2-hydroxybenzoate); ANTICHOLIUM; RefChem:56715; DTXCID501022781; 200-343-8; Eserine salicylate; Physostigmine (salicylate); MLS000028388; SMR000058606; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate 2-hydroxybenzoate; [(3Ar,8bS)-3,4,8b-trimethyl-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]indole-3,4-diium-7-yl] N-methylcarbamate;2-oxidobenzoate; Physostol salicylate; SR-01000075341; 57-64-7 (salicylate); UNII-2046ZRO9VU; CCRIS 3405; Physostigmine salicylate [JAN]; Physostigmine, salicylate (1:1); Antilirium (TN); AR-44; EINECS 200-343-8; Physostigmine salicylate [USP:JAN]; MFCD00135659; TL-1380; Spectrum_000223; Opera_ID_194; RCRA waste no. P188; Physostigmine salicylate CRS; SCHEMBL41555; KBioSS_000703; DivK1c_000339; SPECTRUM1500486; CHEMBL338975; orb1224614; orb1310908; SCHEMBL29787035; HMS501A21; HY-B1266R; KBio1_000339; KBio2_000703; KBio2_003271; KBio2_005839; NINDS_000339; HMS1920H12; HMS2091P16; HMS2235G19; Pharmakon1600-01500486; HY-B1266; Physostigmine salicylate (JAN/USP); CCG-39918; EBC-75102; EX-A11396; NSC757275; PHYSOSTIGMINE SALICYLATE [MI]; AKOS037515711; Physostigmine (salicylate) (Standard); NSC 757275; SDCCGMLS-0002925.P003; IDI1_000339; PHYSOSTIGMINE SALICYLATE [MART.]; PHYSOSTIGMINE SALICYLATE [VANDF]; NCGC00024464-02; PHYSOSTIGMINE SALICYLATE [USP-RS]; PHYSOSTIGMINE SALICYLATE [WHO-DD]; PHYSOSTIGMINE SALICYLATE [WHO-IP]; AC-37462; DA-56832; Eserine salicylate salt, >=97.0% (N); MS-27151; CS-0013051; NS00078948; PHYSOSTIGMINI SALICYLAS [WHO-IP LATIN]; D02418; PHYSOSTIGMINE SALICYLATE [EP MONOGRAPH]; PHYSOSTIGMINE SALICYLATE [USP MONOGRAPH]; SR-01000075341-3; SR-01000075341-5; SR-01000075341-7; Q27121383; Physostigmine salicylate, European Pharmacopoeia (EP) Reference Standard; Physostigmine salicylate, United States Pharmacopeia (USP) Reference Standard; (3aS,8aR)-1,3a,8-trimethyl-5-(methylcarbamoyloxy)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indolium salicylate; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate;2-hydroxybenzoic acid; 2-Hydroxybenzoic acid--(3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate (1/1)Synonyms
